Challenges in the development of mGluR5 positive allosteric modulators: The discovery of CPPHA

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 5, 2007, Pages 1386-1391

  Zhao, Zhijian ^a   Wisnoski, David D ^a   O'Brien, Julie A ^a   Lemaire, Wei ^a   Williams Jr , David L ^a   Jacobson, Marlene A ^a   Wittman, Marion ^a   Ha, Sookhee N ^a   Schaffhauser, Herve ^a   Sur, Cyrille ^a   Pettibone, Doug J ^a   Duggan, Mark E ^a   Conn, P Jeffrey ^a,b   Hartman, George D ^a   Lindsley, Craig W ^a,b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Allosteric modulator; MGluR5; Potentiation

Indexed keywords

BENZAMIDE DERIVATIVE; METABOTROPIC RECEPTOR 5; N [4 CHLORO 2 [(1,3 DIOXO 1,3 DIHYDRO 2H ISOINDOL 2 YL)METHYL]PHENYL] 2 HYDROXYBENZAMIDE; UNCLASSIFIED DRUG;

ALLOSTERISM; ANIMAL CELL; ARTICLE; BINDING SITE; BROMINATION; CONTROLLED STUDY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; NONHUMAN; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; ANIMALS; BENZAMIDES; HUMANS; PHTHALIMIDES; RATS; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33846936284     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.11.081     Document Type: Article

References (16)

1. O'Brien J.A., Lemaire W., Chen T.-B., Chang R.L.S., Jacobson M.A., Ha S., Lindsley C.W., Sur C., Pettibone D.J., Conn P.J., and Williams Jr. D.L. Mol. Pharmacol. 64 (2003) 731
2. O'Brien J.A., Lemaire W., Wittmann M., Jacobson M.A., Ha S.N., Wisnoski D.D., Lindsley C.W., Schaffhauser H.J., Sur C., Duggan M.E., Pettibone D.J., Conn J., and Williams D.L. J. Pharmacol. Exp. Therapeut. 309 (2004) 568
3. Lindsley C.W., Wisnoski D.D., Duggan M.E., Leister W.H., Huff J.R., Williams Jr. D.L., O'Brien J.A., Lemaire W., Sur C., Pettibone D., Kinney G., and Burno M. J. Med. Chem. 47 (2004) 5825
4. Kinney G.G., O'Brien J.A., Lemaire W., Burno M., Bickel D.J., Clements M.K., Wisnoski D.D., Lindsley C.W., Tiller P.R., Smith S., Jacobson M.A., Sur C., Duggan M.E., Pettibone D.J., and Williams Jr. D.W. J. Pharmacol. Exp. Therapeut. 313 (2005) 199
5. Williams Jr. D.L., and Lindsley C.W. Curr. Topics Med. Chem. 5 (2005) 825
6. Lindsley C.W., Shipe W.D., Wolkenberg S.E., Theberge C.R., Williams Jr. D.L., Sur C., and Kinney G.G. Curr. Topics Med. Chem. 8 (2006) 771 and references therein
7. Lindsley C.W., Wolkenberg S.E., Shipe W., and Williams Jr. D.L. Curr. Opin. Drug Disc. Dev 8 (2005) 449
8. Zhang Y., Rodriguez A.L., and Conn P.J. J. Pharmacol. Exp. Therapeut. 315 (2005) 1212
9. Liu F., Zhang G., Hornby G., Vasylyev D., Bowlby M., Park K., Gilbert A., Marquis K., and Andree T.H. Eur. J. Pharmacol. 536 (2006) 262
10. 50 for potentiation (ranging from 9.4% to 32.8%), is detailed in Table of Ref. 2. Note that Figure 3 in the present paper represents the effect of several fixed concentrations of test compound on the agonist concentration-response curve.
11. Leister W.H., Strauss K.A., Wisnoski D.D., Zhao Z., and Lindsley C.W. J. Comb. Chem. 5 (2003) 322
12. Lindsley C.W., Zhao Z., Leister W.H., Robinson R.G., Barnett S.F., Defeo-Jones D., Jones R.E., Hartman G.D., Huff J.R., Huber H.E., and Duggan M.E. Bioorg. Med. Chem. Lett. 15 (2005) 761
13. +, 407.0799; found 407.0793.
14. Booth R.J., and Hodges J.C. J. Am. Chem. Soc. 119 (1997) 4882
15. Sorrell T.N., and Pigge F.C. J. Org. Chem. 58 (1993) 784
16. Bookser B.C., and Bruice T.C. J. Am. Chem. Soc. 113 (1991) 4208